WinstonWınston
Back
Inspire Medical Systems logo

Inspire Medical Systems

INSP
54
Medical - Devices · Healthcare
Price
$62.36
+1.09 (+1.78%)
Market Cap
$1.80B
Winston Score
54
Winston is curious
Mixed quality — meaningful strengths and weaknesses.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Mixed
Growth
Good
Cash Flow
Exceptional
Stability
Good
Valuation
Good

Share count rising — dilution

+9.1% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 27.3M (2021) → 29.8M (2025)

Winston Score History

The full picture

Inspire Medical Systems makes a small implantable device that treats sleep apnea — a condition where people stop breathing repeatedly during sleep. The device, called the Inspire system, is surgically placed inside the chest and uses mild electrical signals to keep the airway open while a patient sleeps. It is sold to hospitals and surgical centers, and is used by patients who cannot tolerate the more common CPAP mask treatment.

The company earns revenue by selling the Inspire implant and related components to healthcare providers, with each procedure generating a one-time device sale. Inspire operates primarily in the United States, with a growing presence in Europe, and has built a strong position as the only FDA-approved hypoglossal nerve stimulation device for sleep apnea on the market. Its main growth driver is expanding the number of trained surgeons and covered insurance plans, while its key risk is its dependence on a single product in a market that larger medical device companies could eventually enter.

Politician Trades

1 trades / 12mo

0 Congressional buys and 1 sell on INSP in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-7.6% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+109.1% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$103M/ year

Declining (-10% vs prior year)

11.3% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

5.7%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$415M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Inspire Medical Systems's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
85.5%
Premium pricing power — 85.5% gross margin
Profit after running costs
Operating Margin
-0.3%
Losing money on operations — -0.3%
Return on the money invested
ROCE
6.6%
Weak — 6.6% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+4.3%
Slow sales growth (+4.3% YoY)
Profit growth
EPS YoY
+161.8%
Earnings growing fast (+161.8% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
116%
Turns 116% of profit into real cash
Spare cash per sale
FCF Margin
13.0%
Converts sales into free cash efficiently (13.0%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
406.94x
Comfortably covers interest (406.9x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
13.4x
Attractive valuation — P/E 13.4

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year
P/E vs Forward
-16.6
SLOWING
Earnings expected to fall — forward P/E higher than today

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial